Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2001 to 2050 of 2990 results for all

  1. Bair Hugger for measuring core temperature during perioperative care (MIB99)

    NICE has developed a medtech innovation briefing (MIB) on Bair Hugger for measuring core temperature during perioperative care .

  2. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

  3. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

  4. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.

  5. Faltering growth (QS197)

    This quality standard covers recognising and managing faltering growth in babies (aged up to 1 year) and preschool children (aged over 1 year). It describes high-quality care in priority areas for improvement.

  6. Intermediate care including reablement (QS173)

    This quality standard covers referral and assessment for intermediate care and how to deliver the service. It covers bed-based intermediate care, crisis response, home-based intermediate care and reablement. It describes high-quality care in priority areas for improvement. It does not cover rehabilitation for specific conditions.

  7. Delirium in adults (QS63)

    This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.

  8. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

  9. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

  10. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

  11. Our partners

    NICE's partners

  12. Use of our content for AI purposes

    Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.

  13. Fallopian tube recanalisation by guidewire (HTG44)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.

  14. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

  15. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion

  16. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  17. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

  18. Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)

    NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

  19. Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTG696)

    Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals.

  20. Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (HTG405)

    Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.

  21. Transcranial magnetic stimulation for obsessive-compulsive disorder (HTG548)

    Evidence-based recommendations on transcranial magnetic stimulation for obsessive-compulsive disorder in adults. This involves pulsing electromagnetic energy through the skull to stimulate the brain.

  22. Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.

  23. Percutaneous vertebroplasty (HTG3)

    Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.

  24. Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (HTG479)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

  25. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment (HTG739)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care.

  26. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

  27. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

    Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.

  28. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

  29. Get involved

    Tell us what matters to you, your organisation or your community.

  30. Get involved

    Tell us what matters to you, your organisation or your community.

  31. Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (HTG558)

    Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of the peritoneal cavity with chemotherapy.

  32. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (HTG339)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.

  33. Percutaneous endoscopic laser thoracic discectomy (HTG34)

    Evidence-based recommendations on percutaneous endoscopic laser thoracic discectomy. This involves using a laser to heat and destroy some of the inside of the disc and shrink the part that is sticking out.

  34. Open femoro–acetabular surgery for hip impingement syndrome (HTG270)

    Evidence-based recommendations on open femoro-acetabular surgery for hip impingement syndrome. This involves removing some of the cartilage or bone, with the aim of reshaping the joint surface.

  35. Computed tomography-guided thermocoagulation of osteoid osteoma (HTG27)

    Evidence-based recommendations on computed tomography-guided thermocoagulation of osteoid osteoma. This involves using high-frequency energy to heat the growth and destroy it.

  36. Lumbar subcutaneous shunt (HTG41)

    Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.

  37. Endoscopic submucosal dissection of lower gastrointestinal lesions (HTG212)

    Evidence-based recommendations on endoscopic submucosal dissection of lower gastrointestinal lesions. This involves inserting a camera through the anus and injecting a solution to raise the affected area for removal.

  38. Supraorbital minicraniotomy for intracranial aneurysm (HTG52)

    Evidence-based recommendations on supraorbital minicraniotomy for intracranial aneurysm. This involves clipping or wrapping the aneurysm through a smaller opening made in the skull, above the eyebrow.

  39. Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing (HTG480)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

  40. Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children (HTG47)

    Evidence-based recommendations on balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children. This involves using a balloon to widen the narrow area of the heart to let blood flow through it more easily.

  41. Airglove air warming system for venous access (MIB151)

    NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .

  42. SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)

    NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .

  43. InterDry for intertrigo (MIB192)

    NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .

  44. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

  45. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  46. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (HTG356)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

  47. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  48. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.

  49. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

  50. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.